Explore 3 Stock Ideas & Industry Insights Download Free Report

888-969-2592
Shopping Cart 0
countryflagCA
Login

Home CompaniesXenon Pharmaceuticals Inc

Xenon Pharmaceuticals Inc

Healthcare Biotechnology
PortfolioPortfolio WatchlistWatchlist
Company price
39.17 USD 1.49 ( 3.95%)
Last update at 2026-11-06T21:00:00Z
VOLUME
867351
Market Cap
2895.74M

Momentum Score

…

Xenon Pharmaceuticals Inc., a neuroscience-focused biopharmaceutical company, engages in the development of therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN1101, a novel and potent Kv7 potassium channel opener, which is in Phase 3 clinical trials for the treatment of epilepsy and other neurological disorders. The company has a license and collaboration agreement with the Neurocrine Biosciences, Inc. for the development of NBI-921352, a selective Nav1.6 sodium channel inhibitor that is in Phase 2 clinical trials for the treatment of SCN8A developmental and epileptic encephalopathy, and other indications, including adult focal epilepsy. Xenon Pharmaceuticals Inc. was incorporated in 1996 and is headquartered in Burnaby, Canada.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Day Price Range
37.15
Low
39.20
High
52 Week Price Range
27.98
Low
50.99
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High
AI Summary

Xenon Pharmaceuticals is a clinical-stage biopharmaceutical company developing ion-channel-targeted therapies for epilepsy and other rare neurological disorders. Long-term growth drivers include advancement of clinical programs toward regulatory approval, potential licensing or commercialization partnerships, and addressing unmet needs in seizure and genetic channelopathy markets. The company may benefit from delivering differentiated mechanisms of action that could support meaningful clinical value if trials succeed.

Risk Score
High

Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.

Key Metrics*

Previous Close
37.68
Dividend Yield
-
Revenue TTM
0.00M
Revenue Per Share
-
Gross Profit TTM
-96.33M
Debt / Equity
0.01
ROE
-23.95%
Net Debt
-137.74M
ROCE
-13.95%
Diluted EPS TTM
-2.72

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Income before tax -125.25M -78.89M -29.09M -41.62M -34.50M
Net income -125.37M -78.88M -28.84M -41.59M -34.50M
Selling general administrative 32.81M 21.97M 12.94M 10.80M 8.38M
Gross profit 9.43M 18.44M 32.17M 6.83M -6.00M
Reconciled depreciation 1.62M 0.91M 0.64M 0.43M 0.59M
Ebit -130.77M -79.90M -31.95M -42.82M -36.80M
Ebitda -129.14M -78.99M -31.30M -40.04M -36.21M
Depreciation and amortization 1.62M 0.91M 0.64M 2.78M 0.59M
Non operating income net other 3.89M 0.10M 2.69M 2.63M 0.52M
Operating income -129.14M -78.99M -31.30M -42.82M -38.02M
Other operating expenses 138.58M 97.43M 63.47M 49.65M 38.02M
Interest expense -5.51M 1.01M 0.48M 1.43M 1.39M
Tax provision 0.12M -0.01M -0.26M -0.02M -0.02M
Interest income 8.71M 0.47M 2.28M 2.35M 1.22M
Net interest income 8.71M 0.47M 1.80M 0.92M -0.18M
Income tax expense 0.12M -0.01M -0.26M -0.02M 4.91M
Total revenue 9.43M 18.44M 32.17M 6.83M 0.00M
Total operating expenses 138.58M 97.43M 63.47M 49.65M 32.02M
Cost of revenue - - - 0.00M 6.00M
Total other income expense net 3.89M 0.10M 2.21M 1.20M 3.70M
Net income from continuing ops -125.37M -78.88M -28.84M -41.59M -38.90M
Net income applicable to common shares -124.94M -77.09M -28.01M -40.03M -31.62M
Breakdown 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Type yearly yearly yearly yearly yearly
Date 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Total assets 964.80M 754.15M 572.01M 189.19M 147.70M
Other current assets 6.01M 8.21M 7.25M 4.79M 2.69M
Total liab 36.88M 32.65M 21.97M 17.83M 55.72M
Total stockholder equity 927.92M 721.50M 550.03M 171.35M 91.98M
Other current liab 17.38M 13.72M 0.60M 7.83M 6.34M
Common stock 1436.37M 1065.14M 783.17M 397.75M 294.24M
Capital stock 1436.37M 1065.14M 790.90M 405.48M 301.98M
Retained earnings -665.14M -482.75M -357.37M -278.49M -249.66M
Other liab - - - - 0.71M
Other assets 306.19M 143.66M 0.47M 0.52M 0.24M
Cash 148.64M 57.24M 175.69M 45.01M 24.75M
Total current liabilities 27.27M 22.70M 14.32M 14.78M 43.38M
Current deferred revenue - - 9.29M 3.64M 29.74M
Net debt -137.74M -46.81M -167.43M -41.69M -8.30M
Short term debt 1.30M 0.49M 0.60M 0.27M 4.82M
Short long term debt - - - - 4.65M
Short long term debt total 10.90M 10.44M 8.26M 3.31M 16.45M
Other stockholder equity 156.76M 142.11M 117.50M 45.36M 40.65M
Property plant equipment - 6.50M 4.47M 3.55M 1.66M
Total current assets 644.96M 600.30M 559.02M 181.78M 144.87M
Long term investments 292.79M 128.68M - - -
Net tangible assets - 721.50M 542.30M 163.62M 84.25M
Short term investments 489.44M 534.85M 376.09M 131.99M 116.60M
Net receivables 0.87M 0.99M 2.77M 1.82M 0.81M
Long term debt - - - - 10.89M
Inventory 0.00M -0.99M -2.77M -1.82M -
Accounts payable 8.60M 8.49M 3.82M 3.04M 2.47M
Accumulated other comprehensive income -0.08M -3.00M -0.99M -0.99M -0.99M
Common stock total equity - 1065.14M 783.17M 397.75M 294.24M
Preferred stock total equity - - 7.73M 7.73M 7.73M
Retained earnings total equity - -482.75M -357.37M -278.49M -249.66M
Non currrent assets other 7.40M 7.75M 8.06M 7.40M 2.59M
Deferred long term asset charges - - - - 0.24M
Non current assets total 319.84M 153.85M 12.99M 7.40M 2.83M
Capital lease obligations 10.90M 10.44M 8.26M 3.31M 0.91M
Long term debt total - - - - 10.89M
Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Investments -293.11M -244.72M -14.19M -65.05M -28.48M
Change to liabilities 8.06M 2.97M 2.02M 4.54M 0.78M
Total cashflows from investing activities -296.00M -246.77M -16.82M -66.29M -28.99M
Net borrowings - - -16.74M -16.74M 8.45M
Total cash from financing activities 278.47M 447.54M 85.80M 27.52M 111.59M
Change to operating activities -10.49M -1.52M -0.27M -0.82M -0.93M
Net income -125.37M -78.88M -28.84M -41.59M -34.50M
Change in cash -118.45M 130.68M 20.25M -43.00M 47.27M
Begin period cash flow 175.69M 45.01M 24.75M 67.75M 20.49M
End period cash flow 57.24M 175.69M 45.01M 24.75M 67.75M
Total cash from operating activities -98.43M -69.50M -48.12M -4.63M -34.72M
Issuance of capital stock 277.77M 447.28M 102.46M 27.40M 102.85M
Depreciation 1.62M 0.91M 0.64M 0.43M 0.59M
Other cashflows from investing activities - - - -65.05M -28.48M
Change to inventory - -2.97M -2.02M -4.54M -0.78M
Change to account receivables 1.76M -0.46M -1.03M -0.65M 0.17M
Sale purchase of stock 0.70M 0.26M 102.54M 27.52M 103.14M
Other cashflows from financing activities 0.70M 0.26M 0.08M 0.12M 8.74M
Change to netincome 23.06M 11.12M 5.94M 2.49M -1.13M
Capital expenditures 2.89M 2.05M 2.64M 1.24M 0.51M
Change receivables 1.76M -0.46M -1.03M -0.65M 0.17M
Cash flows other operating -7.56M -5.16M -27.08M 29.63M -0.93M
Exchange rate changes - - - - -0.61M
Cash and cash equivalents changes -115.96M 131.27M 20.85M -43.41M 47.27M
Change in working capital -0.68M -2.65M -26.09M 33.52M 0.03M
Stock based compensation 20.38M 10.02M 5.68M 2.92M 2.62M
Other non cash items 5.66M 1.05M 0.77M 0.22M -4.11M
Free cash flow -101.32M -71.55M -50.76M -5.87M -35.23M

Peer Comparison*

Sector: Healthcare Industry: Biotechnology

Stock Name
Change
(USD)
Price
(USD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to Revenue (x)
Enterprise Value
to EBITDA (x)
XENE
Xenon Pharmaceuticals Inc		 1.49
3.95%		 39.17 - - 181.44 3.35 10874.63 -11.81
NVO
Novo Nordisk A/S		 0.01
0.02%		 40.31 41.58 31.15 2.13 32.99 2.11 4.70
VRTX
Vertex Pharmaceuticals Inc		 4.59
0.85%		 547.09 30.22 24.27 10.36 6.50 9.99 24.66
REGN
Regeneron Pharmaceuticals Inc		 1.45
0.16%		 904.35 29.07 20.12 7.57 3.82 6.95 19.42
ARGNF
argenx SE		 -
-%		 900.30 45.77 31.25 13.84 7.12 11.38 36.06

Profile*

Xenon Pharmaceuticals Inc

Xenon Pharmaceuticals Inc., a neuroscience-focused biopharmaceutical company, engages in the development of therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN1101, a novel and potent Kv7 potassium channel opener, which is in Phase 3 clinical trials for the treatment of epilepsy and other neurological disorders. The company has a license and collaboration agreement with the Neurocrine Biosciences, Inc. for the development of NBI-921352, a selective Nav1.6 sodium channel inhibitor that is in Phase 2 clinical trials for the treatment of SCN8A developmental and epileptic encephalopathy, and other indications, including adult focal epilepsy. Xenon Pharmaceuticals Inc. was incorporated in 1996 and is headquartered in Burnaby, Canada.

3650 Gilmore Way, Burnaby, BC, Canada, V5G 4W8

604 484 3300

https://www.xenon-pharma.com

251

Name Title Year Born
Mr. Ian C. Mortimer C.M.A., CPA, CMA, CPA, M.B.A., MBA Pres, CEO & Director 1976
Ms. Sherry Aulin Chief Financial Officer 1984
Dr. Christopher John Kenney M.D. Chief Medical Officer 1971
Ms. Jodi Regts M.B.A., B.A., MBA VP of Corp. Affairs & Investor Relations NA
Ms. Andrea DiFabio J.D. Chief Legal Officer & Corp. Sec. 1968
Ms. Shelley McCloskey B.A. Exec. VP of HR 1960
Dr. Robin P. Sherrington Ph.D. Exec. VP of Strategy & Innovation 1961
Dr. James R. Empfield Ph.D. Exec. VP of Drug Discovery 1961
Ms. Sheila M. Grant M.B.A., M.Sc., MBA Exec. VP of R&D Operations NA
Dr. Christopher E. Von Seggern M.B.A., M.P.H., M.P.H. M.B.A, Ph.D. Chief Commercial Officer 1979

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Kalkine

3 Mining Stock
Ideas Report

Download a free report with stock ideas and industry insights for general information.

Download Free Report Now → sector image

Top Stocks by Market Cap*

ITH
CAD 2.15
+27.68%
HG
CAD 4.11
+19.13%
PPTA
CAD 27.74
+17.99%
UCU
CAD 2.10
+17.32%
GAU
CAD 3.49
+16.72%
TSU
CAD 29.67
-29.71%
PXT
CAD 19.73
-16.91%
LAS-A
CAD 230.50
-9.25%
IFP
CAD 13.50
-8.35%
NFI
CAD 24.01
-7.80%

Equity Sectors*

  • Basic Materials

    +3.74%

  • Communication Services

    +0.56%

  • Consumer Cyclical

    -0.34%

  • Consumer Defensive

    +0.11%

  • Energy

    +1.33%

  • Financial Services

    -0.26%

  • Healthcare

    +2.54%

  • Industrials

    -0.11%

  • Real Estate

    -0.23%

  • Technology

    +1.91%

  • Utilities

    +1.05%

Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.

Support

Hi! How can we help you today?

Loading…